Medical Condition

advanced solid tumor

Total Trials

46

Recruiting Now

46

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for advanced solid tumor sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — advanced solid tumor Clinical Trials

How many clinical trials are currently recruiting for advanced solid tumor?

ClinicalMetric currently tracks 46 actively recruiting clinical trials for advanced solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 46. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for advanced solid tumor?

advanced solid tumor research spans Phase 1 (44 trials), Phase 2 (18 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a advanced solid tumor clinical trial?

Eligibility criteria for advanced solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Daiichi Sankyo 2 trials

Jiangsu Hansoh Pharmaceutical Co., Ltd. 1 trial

Novartis Pharmaceuticals 1 trial

MonTa Biosciences ApS 1 trial

Broadenbio Ltd., Co. 1 trial

advanced solid tumor

Frequently Asked Questions — advanced solid tumor Clinical Trials

Recruiting Clinical Trials

Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

A Study of XZB-0004 in Patients With Solid Tumors

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

Study of AVZO-021 in Patients With Advanced Solid Tumors

A Study of NBL-028 in Patients With Advanced Solid Tumors

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Clinical Trial of BT02 in Patients With Advanced Solid Tumors

MAQ-001 in Patients With Advanced Solid Tumors

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

AMT-116 in Patients With Advanced Solid Tumors

Study of SGR-3515 In Participants With Advanced Solid Tumors.

A Study of CM350 in Patients With Advanced Solid Tumors

Safety of AM-928 Infusion in Advanced Solid Tumors

TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

A Study of NWY001 in Subjects With Advanced Solid Tumors

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

SW-682 in Advanced Solid Tumors

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Tumor Molecular Profiling in Early Phase Clinical Trials

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors